News Could AI avert a future coronavirus pandemic? Could AI prevent future pandemics by developing an armoury of drugs that work against all coronaviruses?
News AI drug discovery firm Exscientia gets $60M cash injection UK artificial intelligence specialist Exscientia has topped up its coffers with a $60 million Series C funding round that will be used to advance projects into clinical trials.
News GSK adds to COPD pipeline as Exscientia deal bears fruit AI drug research firm Exscientia has delivered the first candidate molecule to its partner GlaxoSmithKline following an R&D tie-up signed in 2017.
News AI drug R&D firm Exscientia expands into Japan AI drug R&D firm Exscientia has announced it has expanded into Japan, after clinching a major research deal with Celgene.
News GSK pursues $10.6bn takeover of cancer biotech Nuvalent GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
